July 20, 2007 – Despite forecasts by analysts at Thomson Financial that Boston Scientific Corp. would earn $150 million in the second quarter of this year, the company came up short at $115 million in the second quarter, or 7.7 cents a share, due to a significant sales slump in implantable defibrillators and coronary stents.
In 2006, Boston Scientific reported a $4.3 billion loss from its April 2006 purchase of Guidant Corp. Excluding special charges related to the acquisition, the company's profit fell 56 percent from the second quarter of 2006.

Source: Wall Street Journal Online

July 20, 2007 - U.S. doctors implanted fewer coronary stents in June than any other month in the last year, according to a market researcher, indicating that medical studies critical of the devices appear to be having a sustained impact.

July 20, 2007 – Oraganogenesis Inc. announced that it has received regulatory approval in Canada and Europe for BioSTAR, a device that incorporates a bioresorbable collagen scaffold used to treat patent foramen ovale (PFO), a hole in the heart that is usually asymptomatic.

July 19, 2007 – Abbott announced that the first patient was enrolled in its XIENCE V SPIRIT WOMEN clinical trial, the first clinical trial designed to study the safety and effectiveness of drug eluting stent treatment in women.

July 19, 2007 – AtCor Medical Holdings Ltd., the developer and marketer of the SphygmoCor system, which noninvasively measures central blood pressures, announced that it has signed an $1.8 million deal with three leading international pharmaceutical companies to supply SphygmoCor systems and clinical trial support services for new and ongoing drug trials in Europe and the United States.

July 18, 2007 - Abiomed Inc. announced that its Impella 2.5 and Impella 5.0 circulatory support technologies, new catheter-based circulatory support technology for heart failure patients, have been approved for use in Canada by Health Canada's Therapeutic Products Programme (TPP). In addition, the Company also announced that the first patients in Canada have received treatment with the Impella 2.5 technology at the Peter Munk Cardiac Centre at Toronto General Hospital.

July 18, 2008 - Cardium Therapeutics announced that the FDA has given it clearance for fast track designation to its lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), designed to treat myocardial ischemia.

July 18, 2007 - Cardium Therapeutics and its operating unit, InnerCool Therapies, have released its new CoolBlue surface temperature modulation system and RapidBlue endovascular temperature modulation system used for temperature modulation therapy in cardiac arrest patients.

July 18, 2007 - In a related study of over 25,000 initially healthy women, higher triglyceride levels measured after not fasting is associated with an increased risk for cardiovascular events, but his association was not found for triglyceride levels measured after fasting, according to a study in the July 18 issue of JAMA.

July 18, 2007 - An analysis based on computerized simulation models suggests that the lifetime risk of cancer associated with radiation exposure from a computed tomography (CT scan) coronary angiography varies widely, with the risk greater for women and younger patients, according to a study in the July 18 issue of JAMA.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now